The dawn of the dual-target era in respiratory disease: promise, pitfalls, and a roadmap for bispecific antibodies
Bispecific antibodies targeting two inflammatory pathways are entering respiratory medicine at an unprecedented pace. TSLP/IL-13 bispecifics have progressed into mid-to-late-stage clinical development, with two distinct molecules (lunsekimig and CM512)…